# A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects

> **NCT00075231** · PHASE2 · COMPLETED · sponsor: **Abbott** · enrollment: 150 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Kaletra® (lopinavir/ritonavir)
- **DRUG:** Combivir® (lamivudine, zidovudine)
- **DRUG:** Sustiva® (efavirenz)

## Key facts

- **NCT ID:** NCT00075231
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 150 (—)
- **Last updated:** 2006-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00075231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00075231, "A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00075231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*